跳至主要内容
临床试验/ISRCTN24953404
ISRCTN24953404已完成不适用

Memantine for AGitation in Dementia

East Kent Hospitals Research and Development Committee (UK)0 个研究点目标入组 164 人开始时间: 2006年10月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
164

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Residential/inpatients
  • 2. Alzheimers-McKhann Criteria and Haschinski less than four
  • 3. Mini-Mental State Examination (MMSE) score less than or equal to 19
  • 4. Clinically significant agitation requiring treatment
  • 5. Cohen-Mansfield Agitation Inventory (CMAI) score more than or equal to 45
  • 6. Aged 55 years or more

排除标准

  • 1. Memantine use in four weeks prior
  • 2. On cholinesterase inhibitors for less than three months and dose not stable
  • 3. Anti-psychotic, antibiotic, anti-epileptic, anti-depressant, benzodiazepine, lithium, or hypnotic dose alteration in two weeks prior to start
  • 4. Antiparkinsonsian medication
  • 5. Hypersensitivity to memantine or components
  • 6. Severe renal impairment
  • 7. Epilepsy, history of convulsions or seizure, or receiving anti-epileptics
  • 8. Concomitant usage of N-Methyl-D-Aspartic acid (NMDA) antagonists amantadine, ketamine, dextromethorphan
  • 9. Recent Myocardial Infarction (MI), uncompensated Congestive Cardiac Failure (CCF) and uncontrolled hypertension
  • 10. Severe, unstable or poorly controlled medical illness
  • 11. Disability which affects ability to complete study
  • 12. Active malignancy
  • 13. Delirium, pain or medical illness as a cause of agitation
  • 14. Any important drug interactions prohibited during study and in 14 days prior: analgesic (dextromethorpan), dopaminergics (amantadine, warfarin)

研究者

发起方
East Kent Hospitals Research and Development Committee (UK)

相似试验

Memantine for AGitation in Dementia | 临床试验